Boston Scientific (NYSE:BSX) Sets New 52-Week Low – Should You Sell?

Boston Scientific Corporation (NYSE:BSX) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $45.91 and last traded at $45.9580, with a volume of 6156087 shares traded. The stock had previously closed at $46.92.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Citigroup decreased their price objective on Boston Scientific from $87.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, May 28th. BTIG Research reaffirmed a “buy” rating and issued a $65.00 price objective on shares of Boston Scientific in a research report on Tuesday. Wells Fargo & Company reiterated an “equal weight” rating and issued a $55.00 target price (down from $75.00) on shares of Boston Scientific in a research note on Thursday, May 28th. Finally, Stifel Nicolaus set a $75.00 target price on Boston Scientific in a research report on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.08.

Boston Scientific Stock Performance

The company has a market cap of $67.33 billion, a PE ratio of 18.95, a P/E/G ratio of 0.86 and a beta of 0.56. The stock’s 50 day simple moving average is $55.05 and its two-hundred day simple moving average is $73.22. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific announced that its board has initiated a share buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In other news, Director Cheryl Pegus purchased 1,770 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the purchase, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director David C. Habiger acquired 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 9,800 shares of company stock worth $554,012 over the last three months. 0.34% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of BSX. FWL Investment Management LLC acquired a new position in shares of Boston Scientific during the 2nd quarter valued at $26,000. Swiss RE Ltd. purchased a new position in Boston Scientific in the fourth quarter valued at about $26,000. Garton & Associates Financial Advisors LLC purchased a new position in Boston Scientific in the fourth quarter valued at about $26,000. Colonial Trust Co SC lifted its stake in shares of Boston Scientific by 502.2% during the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 231 shares in the last quarter. Finally, Bangor Savings Bank lifted its stake in shares of Boston Scientific by 94.7% during the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 142 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.